Neutropenia Associated With T-Cell Large Granular Lymphocyte Leukemia: Long-Term Response to Cyclosporine Therapy Despite Persistence of Abnormal Cells

By Raman Sood, Carleton C. Stewart, Peter D. Aplan, Hiroyuki Murai, Pamela Ward, Maurice Barcos, and Maria R. Baer

T-cell large granular lymphocyte (T-LGL) leukemia is clinically indolent, but is associated with severe neutropenia in approximately 50% of cases. The pathogenesis of the neutropenia is unclear. We report reversal of severe neutropenia associated with T-LGL leukemia in five patients treated with cyclosporine (CSA). All five had persistent neutrophil counts below 0.5 x 10^9/L, two had agranulocytosis, and four had recurrent infections. Increased populations of LGL were present in blood and marrow, with a T-LGL immunophenotype (CD3+CD8+CD16-CD56-CD57+) shown by multiparameter flow cytometry, and clonal T-cell receptor (TCR) gene rearrangements in two of two pretreatment blood samples studied. CSA was initiated at doses of 1 to 1.5 mg/kg orally every 12 hours, with subsequent dose adjustments based on trough serum levels. Four patients attained normal neutrophil counts with CSA alone; one required addition of low-dose granulocyte-macrophage colony-stimulating factor. Time to attainment of 1.5 x 10^9/L neutrophils ranged from 21 to 75 days. Attempts to taper and withdraw CSA resulted in recurrent neutropenia. Three patients have maintained normal neutrophil counts on continued CSA therapy for 2, 8, and 8.5 years. Two patients died 1.7 and 4.6 years after initiation of CSA despite normal neutrophil counts—one of metastatic melanoma and one of complications after aortofemoral bypass surgery. Despite resolution of neutropenia, increased populations of T-LGL cells have persisted in all patients during CSA therapy, as shown by morphology and flow cytometry and by the presence of clonal TCR gene rearrangements in four patients' posttreatment blood samples. We conclude that CSA is an effective therapy for neutropenia associated with T-LGL leukemia, and that resolution of neutropenia despite persistence of abnormal cells implies that CSA may inhibit T-LGL secretion of yet unidentified mediators of neutropenia.

© 1998 by The American Society of Hematology.

MATERIALS AND METHODS

 Patients. Six patients with T-LGL leukemia were seen at Roswell Park Cancer Institute (Buffalo, NY) between 1989 and 1995. The diagnosis of T-LGL leukemia was established by the presence of increased populations of LGL in the peripheral blood with T-LGL immunophenotypes (see below). One patient had maintained absolute neutrophil counts (ANC) between 0.8 and 1.2 x 10^9/L for 20 years without any therapy, and has continued to be observed with stable neutrophil counts without therapeutic intervention. The other five patients had persistent ANCs below 0.5 x 10^9/L. These five patients were treated with CSA.

 CSA therapy. Patients were treated with daily oral CSA (Sandimmune, Sandoz, East Hanover, NJ). CSA was initiated at a dose of 1 to 1.5 mg/kg orally every 12 hours. Doses were gradually increased until ANC values increased to 1.5 x 10^9/L, while maintaining trough cyclosporine levels in therapeutic range (250 to 400 ng/mL). One patient did not respond to CSA alone, and recombinant human granulocyte-macrophage CSF (GM-CSF; Schering-Plough, Kenilworth, NJ) was added at a dose of 1.5 µg/kg subcutaneously daily. After resolution of neutropenia, CSA was maintained for 6 years without further neutropenia. Three patients have maintained normal neutrophil counts on continued CSA therapy for 2, 8, and 8.5 years. Two patients died 1.7 and 4.6 years after initiation of CSA despite normal neutrophil counts—one of metastatic melanoma and one of complications after aortofemoral bypass surgery. Despite resolution of neutropenia, increased populations of T-LGL cells have persisted in all patients during CSA therapy, as shown by morphology and flow cytometry and by the presence of clonal TCR gene rearrangements in four patients' posttreatment blood samples. We conclude that CSA is an effective therapy for neutropenia associated with T-LGL leukemia, and that resolution of neutropenia despite persistence of abnormal cells implies that CSA may inhibit T-LGL secretion of yet unidentified mediators of neutropenia. CSA appears to represent effective therapy for neutropenia associated with T-LGL leukemia.
nia, CSA doses were tapered to the lowest doses at which therapeutic responses were maintained.

**Multiparameter flow cytometry.** Peripheral blood mononuclear cell expression of the CD3, CD8, CD16, CD57, and CD56 antigens was studied by multiparameter flow cytometry using the Leu4, Leu2, Leu11, Leu7 (Becton Dickinson, San Jose, CA), and NKH1 (Coulter, Hialeah, FL) monoclonal antibodies. A mononuclear gate was created by gating out granulocytes in the forward versus side scatter display. Populations of T-LGL, defined by coexpression of CD3 and CD57, were measured in pretreatment and posttreatment blood samples. For Patient 4, in whom CD57 was not studied pretherapy and whose T-LGL cells coexpressed CD3 and CD56, CD3+56+ counts were compared in pretreatment and posttherapy samples. To determine a normal range for CD3+56+ cells, cells coexpressing these two antigens were measured by multiparameter flow cytometry in peripheral blood samples from 10 normal donors. A normal range of 0.128 ± 0.118 × 10^9/L (mean ± SD) was established. The normal range for CD3+56+ cells in the same 10 donors was 0.098 ± 0.098 × 10^9/L.

**Southern blot analysis.** Rearrangement of the TCR-β subunit gene was studied by Southern blot analysis using a probe for the constant region. Ten-microgram aliquots of genomic DNA extracted from peripheral blood mononuclear cells were digested with Hind III, EcoRI, and BamHI (New England Biolabs, Beverly, MA). Digested DNA was size-separated by electrophoresis in 0.8% agarose gels (Seakem GTG; FMC Bioproducts, Rockland, ME), transferred to Zetabind (Cuno, Meriden, CT), and hybridized with a radiolabeled 400-bp Bgl II/Pst I Cγ2β genomic probe.

To detect TCR-γ gene rearrangements, DNA digested with HindIII, EcoRI, and BamHI was hybridized with a Cγ1 probe. For TCR-δ gene rearrangement analysis, DNA digested with EcoRI, BamHI, and SstI was hybridized with a Jδ1 probe.

**Polymerase chain reaction (PCR).** PCR was performed using a panel of 24 TCR-β chain variable region (TCR-Vβ) and generic TCR-β chain joining region (TCR-Jβ) primers. TCR-Vβ primers were fluorescently labeled. Amplification reagents included 300 ng of DNA template; 1.5 mM MgCl₂; 20 mM Tris-HCl, pH 8.4; 50 mM KCl; 0.2 mM dNTPs; 7% dimethyl sulfoxide; and 0.1 µg/mL of each primer in a total volume of 100 µL, to which 1 U of Taq polymerase (GIBCO, Grand Island, NY) was added. Thermal cycling was performed in a DNA thermal cycler (Perkin-Elmer Cetus, Norwalk, CT) as follows: an initial denaturation for 5 minutes at 94°C, then 1 minute at 94°C, 1 minute at 60°C, and 2 minutes at 72°C for 35 cycles. One microliter of each PCR product was loaded on a 6% denaturant polyacrylamide gel, electrophoresed, and scanned on a Genescanner 373 (Applied Biosystems, Foster City, CA).

**RESULTS**

Pretreatment clinical data for the five patients with severe neutropenia associated with T-LGL leukemia are shown in Table 1. Age at presentation ranged from 45 to 76 years (median, 62 years). Three patients were men and two were women. All five patients had persistent neutrophil counts below 0.5 × 10^9/L; two of the five had agranulocytosis. Four patients had recurrent infections, including pneumonia, sinusitis, cutaneous abscesses, and urinary tract infections. One patient (Patient 3) was also anemic, with a hemoglobin level of 8.8 g/dL, a mean corpuscular volume of 101 µ, a low reticulocyte count, and absence of red blood cell antibodies. The other four patients had normal hemoglobin values. All five patients had normal platelet counts. Two patients had splenomegaly at presentation. Two patients had rheumatoid factor; one of the two (Patient 4) had a polyarthritis that was consistent with rheumatoid arthritis, but the other (Patient 5) had minimal symptoms and signs of arthritis.

Pretreatment bone marrow biopsies were hypocellular in three patients, normocellular in one, and hypercellular in one. Granulocytic hypoplasia was present in all cases, with myeloid to erythroid ratios ranging between 1:1 and 1:6. Myeloid maturation was normal, without dysplasia or maturation arrest. Erythroid maturation was also normal in all patients. Patient 3, the patient with anemia, had 63% erythroblasts in his pretreatment marrow, with normal maturation. LGL were seen in marrow aspirates in all cases. Lymphoid nodules were present in four patients’ pretreatment bone marrow biopsies.

All five patients had increased populations of LGL shown in peripheral blood smears. Immunophenotyping performed by multiparameter flow cytometry showed T-LGL immunophenotypes in all five cases (Table 2). CD3, CD8, and CD57 were coexpressed on T-LGL cells in all five. CD16 was also expressed on the abnormal population in two cases, and CD56 was expressed on the abnormal population in all five cases (Table 2). CD3, CD8, and CD57 were coexpressed on T-LGL cells in all five. CD16 was also expressed on the abnormal population in two cases, and CD56 was in one.

**Table 1. Pretreatment Clinical Characteristics of Patients With T-LGL Leukemia**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age/Sex</th>
<th>Neutropenia</th>
<th>Recurrent Infections</th>
<th>Anemia</th>
<th>Splenomegaly</th>
<th>Arthritis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>62F</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>76M</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>45M</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>72M</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>5</td>
<td>50F</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

**Table 2. T-LGL Immunophenotypes**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Immunophenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CD3-CD8-CD16-CD56-CD57</td>
</tr>
<tr>
<td>2</td>
<td>CD3-CD8-CD16-CD56-CD57</td>
</tr>
<tr>
<td>3</td>
<td>CD3-CD8-CD16-CD56-CD57</td>
</tr>
<tr>
<td>4</td>
<td>CD3-CD8-CD16-CD56-CD57</td>
</tr>
<tr>
<td>5</td>
<td>CD3-CD8-CD16-CD56-CD57</td>
</tr>
</tbody>
</table>

**Abbreviations:** F, female; M, male.
(Patient 3) to the combination of CSA and low-dose GM-CSF. All five patients tolerated cyclosporine therapy well. The only toxicities were mild hypertension in one patient and reversible renal dysfunction in another.

Despite normalization of neutrophil counts, increased populations of T-LGL persisted in all five patients' blood during CSA therapy. Posttreatment peripheral blood smears continued to show increased populations of LGL. Pretreatment and posttreatment T-LGL counts determined by multiparameter flow cytometry are compared in Table 4. Post-CSA T-LGL counts were lower than pretreatment counts in two patients (Patients 1 and 5), but were similar to pretreatment counts in the other three. Figure 1 shows populations of T-LGL cells demonstrated by multiparameter flow cytometry in Patient 5's blood before initiation of CSA therapy and after response to CSA.

TCR gene rearrangement studies were performed on posttreatment blood samples from all five patients both by Southern blot analysis and by PCR. Clonal TCR-β gene rearrangements were shown in posttreatment samples from four patients both by Southern blot analysis and by PCR. Figure 2 shows TCR-β gene rearrangements demonstrated by Southern blot analysis in Patient 5's peripheral blood cells before and after CSA therapy, and Fig 3 shows clonal rearrangement of the TCR-Vβ4 demonstrated by PCR in Patient 5's blood cells after CSA therapy. Patient 1's posttreatment blood cells did not show convincing evidence of a TCR-β gene rearrangement by Southern blot analysis or by PCR, and neither TCR-γ nor TCR-δ gene rearrangement was shown by Southern blot analysis. A pretreatment sample from Patient 1 was not available for study.

Pre-CSA and post-CSA bone marrow aspirate smears and biopsy sections were compared in three patients (Table 5). Although the lymphocyte mass (the percentage of lymphocytes in the bone marrow aspirate smear multiplied by the average cellularity of the bone marrow biopsy) decreased after treatment with CSA, the percentage of lymphocytes remained elevated in all three patients, as did the proportion of lymphocytes with LGL morphology (20% to 60%). All three patients' bone marrow samples showed marked absolute granulocytic hypoplasia before CSA therapy. There was a modest increase in granulocyte mass (the percentage of granulocytes in the bone marrow aspirate smear multiplied by the average cellularity of the bone marrow biopsy) in posttherapy samples, but granulocytic hypoplasia persisted in all three patients. Thus, despite normalization of ANCs, bone marrow samples, like peripheral blood samples, showed evidence of persistent involvement by LGL leukemia.

After attainment of responses in all five patients, attempts were made to taper CSA doses to the lowest levels at which therapeutic responses were maintained. The maintenance dose of CSA was lower than the induction dose in all but one patient

<table>
<thead>
<tr>
<th>Table 3. Clinical Response to CSA Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient</td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 4. White Blood Cell, Absolute Neutrophil, and LGL Counts Before and After CSA Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient</td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
</tbody>
</table>

Abbreviation: WBC, white blood cell.
Although CSA doses could be decreased, attempts to progressively taper and withdraw CSA resulted in recurrent neutropenia. Of note, neutropenia recurred when CSA therapy was tapered and withdrawn in Patient 3, the patient who had required the addition of low-dose GM-CSF to CSA to achieve a response. Recurrence of neutropenia when CSA was withdrawn showed that this patient had in fact responded to CSA as well as GM-CSF.

The duration of follow-up ranges from 1.7 to 8.5 years (median, 4.6 years). Three of the five patients are alive, with normal neutrophil counts. Patient 3 died of metastatic melanoma 1.7 years after initiation of CSA. Patient 4 died of postoperative complications following aorto-femoral bypass surgery 4.6 years after initiation of CSA, despite a normal neutrophil count.

DISCUSSION

We report sustained reversal of neutropenia associated with T-LGL leukemia in five patients treated with CSA. Our report represents the largest series of patients with LGL leukemia treated with CSA and has the longest follow-up. This report highlights the relatively low doses of CSA required to treat this disorder, the favorable toxicity profile of CSA therapy, and the rapid onset of clinical response. We have also shown the persistence of T-LGL cells despite resolution of neutropenia, and the need for ongoing maintenance CSA therapy to sustain responses.

The diagnosis of T-LGL leukemia was established in our patients by morphological demonstration of increased populations of LGL in peripheral blood and by demonstration of the CD3⁺CD8⁺CD57⁺ immunophenotype by multiparameter flow cytometry. LGL counts in normal peripheral blood have been reported as $0.198 \pm 0.112 \times 10^9/L$, $0.210 \pm 0.020 \times 10^9/L$, and $0.223 \pm 0.099 \times 10^9/L$, although higher values of $0.630 \pm 0.261 \times 10^9/L$ in men and $0.350 \pm 0.176 \times 10^9/L$ in women were found in one study. Using coexpression of CD3 and CD57 to identify T-LGL, we established a normal range of $0.128 \pm 0.118 \times 10^9/L$. An LGL count of $2 \times 10^9/L$ was used as the criterion for diagnosing LGL leukemia in some earlier studies. It has subsequently been recognized that otherwise typical LGL leukemia patients may have LGL counts below $2 \times 10^9/L$. The updated criterion for the diagnosis of LGL
leukemia is the demonstration of clonal expansion of a population of granular lymphocytes. Three of our patients had LGL counts of $2 \times 10^9/L$ or greater. The other two had LGL counts below $2 \times 10^9/L$, but had flow cytometric evidence of T-LGL expansion, and also exhibited TCR-β gene rearrangements, albeit in posttreatment samples. Patient 1 in our series had an LGL count of $2 \times 10^9/L$ and had expansion of CD3+CD8+CD57+ cells shown by multiparameter flow cytometry, but did not have convincing evidence of a TCR gene rearrangement in a posttreatment blood sample, despite persistence of increased numbers of T-LGL shown by morphology and flow cytometry. A pretreatment sample was not available for study. The apparent absence of a TCR gene rearrangement in this patient’s cells was surprising, but rare cases of otherwise typical T-LGL leukemia without TCR gene rearrangements have been reported. Of particular note is a report of a patient with T-LGL leukemia who had a clonal cytogenetic abnormality, but did not have a clonal TCR gene rearrangement.

Clonal disorders of T-LGL have an indolent clinical course. Neutropenia is generally the most significant clinical problem in these patients. Neutropenia has been reported in approximately 85% of patients, and severe neutropenia ($<0.5 \times 10^9/L$) is present in approximately 50%. Recurrent bacterial infections resulting from severe neutropenia are the presenting feature in the majority of cases. Anemia and thrombocytopenia are less common (approximately 50% and 20% of patients, respectively), and, when present, are generally mild. Rheumatoid arthritis is diagnosed in approximately 30% of patients with LGL leukemia, but its manifestations are generally mild. Thus, neutropenia represents a life-threatening complication of what is otherwise an indolent disease, and is the major indication for therapy.

The mechanism by which severe neutropenia develops in patients with T-LGL leukemia is not well understood. Neutropenia does not appear to be caused by marrow infiltration, as the extent of bone marrow infiltration by LGL cells is usually not sufficient to explain the severity of the neutropenia, and neutropenia is more common and more severe than anemia and thrombocytopenia. Moreover, neutropenia does not appear to be caused by direct immune suppression. Normal LGL have been shown to suppress GM colony formation, but this phenomenon has not been observed when LGL cells from patients with LGL leukemia have been cocultured with bone marrow from normal donors, nor with autologous marrow.

Immune destruction mediated by granulocyte antibodies may play a role in the neutropenia associated with T-LGL leukemia because anti-granulocyte antibodies are common, shortened neutrophil survival has been shown, and both complement fixation by the IgG fraction and antibody-dependent cell-mediated cytotoxicity have been observed. Nevertheless, peripheral destruction of granulocytes cannot be the only operative mechanism because granulocytic hypoplasia, as was noted in our patients, is a common finding and anti-neutrophil-reactive IgG persists when neutrophil counts normalize in response to methotrexate therapy.

LGL from patients with T-LGL leukemia produce a variety of lymphokines which may play a role in the genesis of neutropenia. Production of interferon-γ has been shown, as has inhibition of myeloid colony growth by interferon-γ. Interleukin-2 (IL-2) synthesis has been demonstrated in T-LGL cells from patients with T-LGL leukemia, and IL-2–mediated autocrine proliferation has been suggested. Finally, tumor necrosis factor-α (TNF-α) synthesis has been shown, and TNF-α synthesis was stimulated by incubation with IL-2.

Neutropenia may arise by more than one mechanism in patients with T-LGL leukemia. Baker et al showed both humoral and cellular suppression of granulopoiesis in a patient with neutropenia associated with a CD3+CD8+CD57+ population. Marrow colony forming unit-GM (CFU-GM) growth was markedly reduced, but normalized after T-cell depletion in the absence of autologous plasma. Addition of either autologous T cells or autologous plasma to cultures caused marked growth inhibition. Humoral suppression of CFU-GM was shown to be mediated by the IgG fraction and seemed to be complement-independent. The patient did not respond to plasmapheresis, aimed at reversing humoral suppression of granulopoiesis, nor to prednisone, cyclophosphamide, or vinblastine therapy, aimed at treating cellular suppression. CSA therapy was initiated based on the idea that it might be effective in inhibiting both cellular immune mechanisms and synthesis of immunoglobulins (see below). Single-agent CSA therapy produced rapid normalization of the neutrophil count, and in vitro studies showed reversal of both humoral and cellular suppression, but only when CSA was present in the culture medium. This in vitro observation suggested the need for ongoing CSA therapy.

CSA is an immunosuppressive agent which inhibits activation of CD4+ lymphocytes, thereby suppressing both cellular and humoral immunity. CSA also inhibits expression of the genes coding for IL-2 and the IL-2 receptor, as well as other cytokines. Our use of CSA to treat neutropenia associated with T-LGL leukemia was predicated on these properties, as well as on earlier reports of the successful use of CSA to treat other immunologically mediated cytopenias, including severe aplastic anemia, pure red cell aplasia, and amegakaryocytic thrombocytopenia. There are five previous reports of successful CSA therapy of neutropenia associated with LGL leukemia, including our own 1989 abstract reporting the early results of treatment of Patients 1 and 2 in the present report. Three other patients successfully treated with CSA alone have been reported. Two had previously been unsuccessfully treated with other agents, including prednisone, cyclophosphamide, vinblastine, and lithium. All three patients received ongoing CSA therapy after resolution of neutropenia. Numbers of T-LGL were unchanged in one patient, but decreased markedly in the other two. Jakubowski et al reported a patient with T-LGL leukemia whose neutropenia, previously unresponsive to prednisone and cyclophosphamide, did not respond to G-CSF alone but responded to the combination of G-CSF and CSA, and who was then able to receive maintenance therapy consisting of G-CSF alone. T-LGL cells were not detectable in this patient during maintenance therapy. CSA has also been used to successfully treat adult-onset cyclic neutropenia, an entity associated with clonal T-LGL proliferation, increased numbers of T-LGL persisted during maintenance CSA therapy. Of interest also is a report of successful CSA therapy of severe anemia in two patients with T-LGL leukemia. As with CSA therapy of neutropenia, expanded populations of T-LGL per-
sisted despite successful therapy of anemia, and maintenance CSAn therapy was needed to sustain responses.

The mechanism of response of T-LGL leukemia to CSA is poorly understood. We postulate that CSA reverses neutropenia associated with T-LGL leukemia by inhibiting T-LGL secretion of inhibitory cytokines as well as synthesis of anti-granulocyte antibodies. Based on our experience with unsuccessful withdrawal of CSA therapy and based on in vitro observations, it seems that maintenance of normal neutrophil counts is dependent on ongoing CSA therapy, albeit in reduced doses. Of note, increased populations of T-LGL persisted in all of our patients despite resolution of neutropenia. Of interest are the cases in the literature in which T-LGL decreased in number or became undetectable coincident with CSA-induced resolution of neutropenia. CSA likely interrupted an autocrine loop in these cases by inhibiting synthesis of IL-2 and possibly other cytokines. It is unclear whether ongoing CSA therapy is needed in cases in which T-LGL cells become undetectable.

Successful CSA therapy of neutropenia associated with T-LGL leukemia in a series of five patients, reported here, suggests that the response rate to CSA is high. Nevertheless, additional, larger prospective trials are needed to define the true rate of response to CSA in this rare disorder. Additionally, mechanisms of response remain to be defined.

ACKNOWLEDGMENT

The authors thank Dr. William Lawrence (Buffalo, NY), Dr Alan Baer (Buffalo, NY), and Dr. Loren Rosenbach (Pittsburgh, PA) for referring patients for this study.

REFERENCES

1. Loughran TP: Clonal disorders of large granular lymphocytes. Blood 82:1, 1993
29. Rustagi PK, Han T, Ziolkowski L, Farolino DL, Currie MS,


Neutropenia Associated With T-Cell Large Granular Lymphocyte Leukemia: Long-Term Response to Cyclosporine Therapy Despite Persistence of Abnormal Cells

Raman Sood, Carleton C. Stewart, Peter D. Aplan, Hiroyuki Murai, Pamela Ward, Maurice Barcos and Maria R. Baer